Digital Agenda

E-Poster Session I

MTP Session I: AML

Session Chair: Lucy Godley

• Familial Predisposition to AML: How Far Are We in the Understanding? |  Lucy A. Godley, MD, PhD  |  The University of Chicago Medicine, Chicago, Illinois, USA
• Beyond BCL2 Inhibition: Prospects for MCL1 Inhibitors and Others  |  Marina Konopleva, MD, PhD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• Single Cell Profiling in AML  |  Koichi Takahashi, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

MTP Session II: ALL        

Session Chair: Wendy Stock

• Approach to the Elderly Patient with ALL  |  Sabina Chiaretti, MD, PhD  |  Sapienza University, Rome, Italy
• Novel Transplant and Post-Transplant Options in ALL  |  Aaron Logan, MD, PhD  |  UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
• Use of BCL2 Inhibitors in ALL  |  Wendy Stock, MD  |  The University of Chicago Medicine, Chicago, Illinois, USA

MTP Session III: NHL        

Session Chair: Mark Roschewski       

• Primary CNS Lymphoma  |  Lakshmi Nayak, MD  |  Dana-Farber Cancer Institute, Boston, Massachusetts, USA
• Prophylaxis and Management of Secondary CNS Lymphoma   |  Mark J. Roschewski, MD  |  National Cancer Institute, Bethesda, Maryland, USA
• Prognostication and Treatment of Burkitt Lymphoma in the Modern Era  |  Adam J. Olszewski, MD  |  Alpert Medical School of Brown University, Providence, Rhode Island, USA

MTP Session IV: NHL        

Session Chair: Philippe Armand        

• Relapsed/Refractory T-cell Lymphoma  |  Pierluigi Porcu, MD  |  Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
• Hodgkin Lymphoma: What to Do When Checkpoint Inhibitors Fail  |  Philippe Armand, MD, PhD  | Dana-Farber Cancer Institute, Boston, Massachusetts, USA
• POD24 in Follicular Lymphoma: What Time has Taught Us  |  Nathan H. Fowler, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

MTP Session V: CML        

Session Chair: Jerald Radich       

• Response and Progression in CML  |  Jerald P. Radich, MD  |  University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
• Importance of BCR-ABL Transcript Type in CML  |  Nick Cross, MA, PhD, FRCPath  |  University of Southampton, Salisbury, United Kingdom
• New Drugs, New Challenges in CML |  Jorge Cortés, MD  |  Georgia Cancer Center at Augusta University, Augusta, Georgia, USA

MTP Session VI: MPN        

Session Chair: Andreas Reiter        

• Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Diagnosis |  Annette S. Kim, MD, PhD, FCAP  |  Brigham and Women’s Hospital, Boston, Massachusetts, USA
• Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment  |  Andreas Reiter, MD  | University Medical Center Mannheim, Mannheim, Germany
• Chronic Eosinophilic Leukemia: Diagnosis and Therapy  |  Jason R. Gotlib, MD, MS  |  Stanford University, Stanford, California, USA

MTP Session VII: MDS        

Session Chair: Guillermo Montalban-Bravo        

• A Primer on the Biology of MDS  |  Simona Colla, PhD  | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• Update on CMML  |  Guillermo Montalban-Bravo, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• Update on Clonal Hematopoiesis  |  Kelly Bolton, MD, PhD  |  Washington University School of Medicine, St. Louis, Missouri, USA

MTP Session VIII: MM       

Session Chair: Sagar Lonial       

Other Plasma Cell Disorders       

• Novel Agents for Waldenstrom's Macroglobulinemia  |  Jorge J. Castillo, MD  |  Dana-Farber Cancer Institute, Boston, Massachusetts, USA
• How to Recognize and Treat MGRS  |  Nelson Leung, MD  |  Mayo Clinic Rochester, Rochester, Minnesota, USA
• Bone Disease in MM  |  Matthew T. Drake, MD, PhD  |  Mayo Clinic Rochester, Rochester, Minnesota, USA

MTP Session IX: CLL      

Session Chair: William Wierda 

Case Studies in CLL       

• 2 Case studies CLL   |  Nicole Lamanna, MD  |  Columbia University and at New York Presbyterian Hospital, New York, New York, USA
• 2 Case studies CLL   |  John M. Burke, MD  |  US Oncology, Aurora, Colorado, USA
• 2 Case studies CLL   |  Deborah M. Stephens, DO  |  The University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, USA

MTP Session X: CT       

Session Chair: Saul Priceman

Cellular Therapies for Solid Tumors       

• TILS for Melanoma  |  Omid Hamid, MD  |  Cedars-Sinai, The Angeles Clinic and Research Institute, Los Angeles, California, USA
• CARS for Solid Tumors  |  Roisin E. O'Cearbhaill, MD  |  Memorial Sloan-Kettering Cancer Center, New York, New York, USA
• CARS for Prostate Cancer  |  Saul Priceman, PhD  |  City of Hope National Medical Center, Duarte, California, USA

MTP Session XI: AML        

Session Chair: Tapan Kadia      

• How Can We Improve on MRD Assessment by Flow Cytometry  |  Sylvie Freeman, DPhil, MBChB, MRCP, FRCPath  |  The University of Birmingham, Birmingham, United Kingdom
• Menin Inhibitors in AML, What are the Prospects?  |  Eunice Wang, MD  |  Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
• Novel Strategies to Treat Elderly with AML  |  Tapan M. Kadia, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

MTP Session XII: ALL        

Session Chair: Partow Kebriaei

• Chemotherapy Free Regimens in ALL  |  Matthew Wieduwilt, MD, PHD  |  OU Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
• Approach to Philadelphia Chromosome Positive ALL   |  Partow Kebriaei, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• Chemoresistance and Drug Profiling in ALL  |  Beat C. Bornhauser, PhD  |  University Children’s Hospital Zurich, Zurich, Switzerland

MTP Session XIII: NHL       

Session Chair: Jorge J. Castillo

• Tailoring Therapy in Waldenstrom Macroglobulinemia  |  Jorge J. Castillo, MD  |  Dana-Farber Cancer Institute, Boston, Massachusetts, USA
• New Agents in Marginal Zone Lymphoma   |  Pier Luigi Zinzani, MD, PhD  |  University of Bologna, Bologna, Italy
• Case Discussion in Rarer Subtypes of Indolent B-Cell Lymphoma  |  Izidore  Lossos, MD  |  University of Miami, Miami, Florida, USA

MTP Session XIV: NHL       

Session Chair: Jeremy Abramson        

• Update on CD19-Directed CAR T-Cell Therapy in B-Cell Lymphoma  |  Federick Locke, MD  |  H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
• Novel Cellular Therapies ​in Development for Lymphoma  |  Barbara Savoldo, MD, PhD  |  University of North Carolina Health, Chapel Hill, North Carolina, USA
• Managing B-Cell Lymphoma Post CAR T-Cell Therapy  |  Jeremy S. Abramson, MD   |  Massachusetts General Hospital, Boston, Massachusetts, USA

MTP Session XV: CML       

Session Chair: Jerry Radich        

• Genomically Guided Therapy in CML  |  Timothy P. Hughes, MD, FRACP, FRCPA  |  South Australian Health and Medical Research Institute, Adelaide, Australia
• Blast Crisis CML  |  Michael Deininger, MD, PhD  |  Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA
• Molecular Testing of CML Patients in 2021: Between Old and New Tools  |  Simona Soverini, MD  |  University of Bologna, Bologna, Italy

MTP Session XVI: MPN  

Session Chair: Andreas Reiter    

• Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Diagnosis  |  Annette S. Kim, MD, PhD, FCAP  |  Brigham and Women’s Hospital, Boston, Massachusetts, USA
• Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment  |  Andreas Reiter, MD  |  University Medical Center Mannheim, Mannheim, Germany
• Chronic Eosinophilic Leukemia: Diagnosis and Therapy  |  Jason R. Gotlib, MD, MS  |  Stanford University, Stanford, California, USA

MTP Session XVII: MDS 

Session Chair: Rami Komrokji   

• Treatment of Lower Risk MDS  |  Rami Komrokji, MD  |  H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
• Treatment of Higher Risk MDS  |  Andrew Brunner, MD  |  Massachusetts General Hospital, Boston, Massachusetts, USA
• Use of Oral Hypomethylating Agents in MDS  |  Guillermo Garcia-Manero, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

MTP Session XVIII: MM    

Session Chair: Suzanne Lenztsch       

Non-BCMA Immunotherapy in MM       

• Next Generation CD38 Antibodies and Antibodies with Novel Targets GPRC5D and FcRH5  |  Thomas G. Martin, MD  |  University of California San Francisco, San Francisco, California, USA
• Next Generation Cellular Therapies: NK Cells, AlloCARs, Vaccines, etc.   |  Nina Shah, MD  |  University of California San Francisco, San Francisco, California, USA
• Infection in the CD38 and Anti-BCMA Era: Prevention and Treatment  |  Noopur Raje, MD  |  Massachusetts General Hospital, Boston, Massachusetts, USA

MTP Session XIX: CLL       

Session Chair: Jennifer Woyach

Relapsed and Refractory CLL      

• Resistance to BCL-2i  |  Constantine S. Tam, MBBS, MD  |  Peter MacCallum Cancer Centre, Victoria, Australia
• Resistance to BTKi  |  Jennifer A. Woyach, MD  |  Ohio State University, Columbus, Ohio, USA
• Cell Based Therapy  |  Thomas Kipps, MD, PhD  |  University of California, San Diego, California, USA

MTP Session XX: CT

Session Chair: Marcela Maus      

Late Toxicities of Cellular Therapies

• Chronic GVHD - New Therapies  |  Daniel R. Couriel, MD, MS  |  University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, USA
• CAR Induced Cytopenia  |  Tania Jain, MBBS, MD  |  John Hopkins University, Baltimore, MD, USA
• Long Term Follow up of CAR T Recipient  |  Marcela V. Maus,MD,PhD   |  Massachusetts General Hospital, Boston, Massachusetts, USA

SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA 

Welcome and Opening Remarks  |  Susan O'Brien  |  President, Society of Hematologic Oncology

SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA 

Hyper CVAD in 2021: Lessons Learned and New Approaches  |  Elias Jabbour, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA 

MRD in ALL: Techniques and Therapeutic Utility  |  Lori Muffly, MD  |  The University of Stanford, Stanford, California, USA

SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA 

Novel CAR-T Constructs for ALL  |  Peggy Peihua Lu, MD, PhD  |  Hebei Yanda Lu Daopei Hospital, Hebei, China

SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA 

Asparaginase: Understanding and Overcoming Toxicities  |  Ibrahim T. Aldoss, MD  |  City of Hope Comprehensive Cancer Center, Duarte, California, USA

SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA 

Novel approaches to T-Cell ALL  |  David T. Teachey, MD  |  Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA 

DEBATE: Optimal Time for Blinatumomab: Is it Time for MRD?  |  Rachel Rau, MD  |  Baylor College of Medicine, Houston, Texas, USA

SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA 

DEBATE: Optimal Time for CAR-T: Is it Time for MRD?  |  Rebecca A. Gardner, MD  |  Seattle Children's Hospital, Seattle, Washington, USA

SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA 

Oral Abstract - ALL-031: The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia |  Shawn Lee, MD | St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Industry Expert Session I

Continued Treatment in AML: The Role of Onureg (azacitidine) tablets

Farhad Ravandi-Kashani, MD | MD Anderson Cancer Center | Houston, TX, USA

This activity is sponsored by Bristol Myers Squibb

Industry Expert Session II

ZYNLONTA™, the First-and-Only CD19-Targeted ADC, for the Treatment of Adults with R/R DLBCL After Two or More Lines of Systemic Therapy | Adolfo Enrique Diaz Duque, MD, MSc | UT Health San Antonio, Mays Cancer Center, San Antonio, Texas, USA

This activity is sponsored by ADC Therapeutics

PLENARY SESSION I

Session Chair: Susan O'Brien  

Managing Patients Relapsed or Refractory to Targeted Therapy | Jennifer R. Brown, MD, PhD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

SESSION II: MYELODYSPLASTIC SYNDROMES 

New Approaches for Lower Risk MDS  |  Uwe Platzbecker, MD  | Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany

SESSION II: MYELODYSPLASTIC SYNDROMES 

New Immunotherapy Approaches for MDS  |  Uma Borate, MD, MS  |  Ohio State University James Cancer Hospital, Columbus, Ohio, USA

SESSION II: MYELODYSPLASTIC SYNDROMES 

NED Inhibition  |  Lionel Adès, MD, PhD  |  Hôpital Saint-Louis, Paris, France

SESSION II: MYELODYSPLASTIC SYNDROMES 

BCL-2 Inhibition in MDS  |  Andrew Wei, MBBS, PhD  |  Alfred Hospital and Monash University, Melbourne, Australia

SESSION II: MYELODYSPLASTIC SYNDROMES 

Targeting p53 in MDS  |  David A. Sallman, MD  |  H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

SESSION II: MYELODYSPLASTIC SYNDROMES 

Oral Abstract: MDS-229: Assessment of Baseline Clinical and Molecular Characteristics in Indolent Chronic Myelomonocytic Leukemia   |  Luis E. Aguirre, MD |  

SESSION III:  ACUTE MYELOID LEUKEMIA

IDH Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy  |  Courtney D. DiNardo, MD, MSCE  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

SESSION III:  ACUTE MYELOID LEUKEMIA

NPM1 Mutated AML: From Bench to Bedside  |  Brunangelo Falini, MD  |  University of Perugia, Perugia, Italy

SESSION III:  ACUTE MYELOID LEUKEMIA

FLT3 mutated AML: Moving Towards Cure   |  Alexander E. Perl, MD  |  University of Pennsylvania, Philadelphia, Pennsylvania, USA

SESSION III:  ACUTE MYELOID LEUKEMIA

Antibody-Based Therapy in AML: Immunotoxins and Bi-specifics  |  Amir Fathi, MD  |  Massachusetts General Hospital, Boston, Massachusetts, USA

SESSION III:  ACUTE MYELOID LEUKEMIA

TP53 Mutated AML: New Horizons  |  Naval Daver, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

SESSION III:  ACUTE MYELOID LEUKEMIA

DEBATE: Is Maintenance Therapy in AML Necessary? YES  |  Farhad Ravandi, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

SESSION III:  ACUTE MYELOID LEUKEMIA

DEBATE: Is Maintenance Therapy in AML Necessary? NO  |  Jeffrey E. Lancet, MD  |  H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

SESSION III:  ACUTE MYELOID LEUKEMIA

Measurable Residual Disease in AML  |  Jacqueline Cloos, PhD  |  Amsterdam UMC, Amsterdam, The Netherlands

SESSION III:  ACUTE MYELOID LEUKEMIA

Oral Abstract - AML-024: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia   |  Curtis Lachowiez, MD |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

SESSION III:  ACUTE MYELOID LEUKEMIA

Oral Abstract - AML-345: Algorithmic Diagnostic Approach and Spectrum of Hematological Malignancies in Patients with Germline Predisposition Syndromes   |  Alejandro Ferrer, PhD |  Mayo Clinic Rochester, Rochester, Minnesota, USA

Poster and Industry Awards Session

E-Poster Session II

INDEPENDENT SATELLITE SYMPOSIUM II

Exploring New Approaches for Treating Patients with Cytopenic Myelofibrosis

John Mascarenhas, MD | Icahn School of Medicine at Mount Sinai, New York, New York, USA
Prithviraj Bose, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Bart L. Scott, MD | Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
 

This CME activity is provided by Medscape. This activity is supported by an educational grant from CTI BioPharma Corp.
For more information and to register for this ISS, go to www.medscape.org/symposium/mf-cytopenic

INDEPENDENT SATELLITE SYMPOSIUM III

Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes

Moderator: Neil Love, MD | Research To Practice | Miami, Florida, USA
Daniel A Pollyea, MD, MS | University of Colorado School of Medicine | Aurora, Colorado, USA
David Sallman, MD | Moffitt Cancer Center | Tampa, Florida, USA
Eunice S Wang, MD | Roswell Park Comprehensive Cancer Center | Buffalo, New York, USA
Courtney D DiNardo, MD, MSCE | The University of Texas MD Anderson Cancer Center | Houston, Texas, USA

This CME activity is provided by Research To Practice. This activity is supported by educational grants from Abbvie Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo, Genentech, a member of the Roche Group, Gilead Sciences Inc and Jazz Pharmaceuticals Inc.
For more information and to register for this ISS, go to http://www.researchtopractice.com/Meetings/ISS-SOHO2021/AML-MDS.

INDEPENDENT SATELLITE SYMPOSIUM IV

Seizing the Day’ with BTK Inhibitors in CLL

Co-Chair and Moderator, Nicole Lamanna, MD | Herbert Irving Comprehensive Cancer Center, New York, New York, USA
Co-Chair and Presenter, Jennifer Woyach, MD | The Ohio State University, Columbus, Ohio, USA

This educational live symposium is accredited by Medical Learning Institute, Inc. for CME/MOC.
This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education.
This activity is supported by an independent educational grant from AstraZeneca.
To register for this live web broadcast, go to PeerView.com/CLL-Virtual2021

BREAKFAST WITH THE EXPERT I

How I Use MRD: European and American Perspectives | Othman Al-Sawaf, MD | University Hospital of Cologne, Cologne, Germany

How I Use MRD: European and American Perspectives | Matthew S. Davids, MD, MMSc | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

SESSION IV: MYELOPROLIFERATIVE NEOPLASMS

Simple Guideline to Systemic Mastocytosis in 2021  |  Jason R. Gotlib, MD, MS  |  Stanford University, Stanford, California, USA

SESSION IV: MYELOPROLIFERATIVE NEOPLASMS

Polycythemia Vera: Is it Time to Rethink Treatment?  |  Francesco  Passamonti, MD  |  University of Insubria, Varese, Italy

SESSION IV: MYELOPROLIFERATIVE NEOPLASMS

Evolution in Prognostication in Myelofibrosis: From IPSS and DIPSS to MIPSS-70 and MYSEC-PM   |  Laura C. Michaelis, MD  |  Medical College of Wisconsin, Milwaukee, Wisconsin, USA

SESSION IV: MYELOPROLIFERATIVE NEOPLASMS

Accelerated Phase of MPN: What Is It and What to Do About It  |  Olatoyosi Sobulo Odenike, MD  |  The University of Chicago Medicine, Chicago, Illinois, USA

SESSION IV: MYELOPROLIFERATIVE NEOPLASMS

Potential New Therapeutic Approaches for Myelofibrosis  |  Srdan Verstovsek, MD, PhD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

SESSION IV: MYELOPROLIFERATIVE NEOPLASMS

Oral Abstract: MPN-133: Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the REVEAL Prospective, Observational Study   |  Carole B. Miller, MD |  Ascension Saint Agnes Hospital, Baltimore, Maryland, USA

SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIA

Molecular and Microenvironmental Basis of Immunodysfunction in CLL  | Silvia Deaglio, MD, PhD  |  University of Turin, Turin, Italy

SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIA

Spectrum/Management of Infections in Patients with CLL  |  Carsten U. Niemann, MD, PhD  |  Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIA

DEBATE: Old Prognostic Markers Still Have a Role in CLL Management  |  Inhye Ahn, MD  |  National Institutes of Health Clinical Center, Bethesda, Maryland, USA

SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIA

DEBATE: Old Prognostic Markers Do Not Have a Role in CLL Management  |  Steven Coutre, MD  |  Stanford University School of Medicine, Stanford, California, USA

SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIA

Approaches to Therapy of Richter Syndrome  |  Davide Rossi, MD, PhD  |  Institute of Southern Switzerland, Bellinzona, Switzerland

SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIA

New Targetable Pathways  |  Alexey V. Danilov, MD, PhD  |  City of Hope National Medical Center, Duarte, California, USA

SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIA

Oral Abstract - CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study   |  Catherine C. Coombs, MD |  The University of North Carolina Cancer Center, Chapel Hill, North Carolina, USA

Industry Expert Session III

Clinical Cases in Polycythemia Vera: When to Intervene With Jakafi® (rollatini) | Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea | David Rizzieri, MD | Duke University Medical Center

This activity is sponsored by Incyte

Industry Expert Session IV

Discover the Role of Two Immunotherapies in Myeloma Treatment

William Velasquez, MD | Memorial Hermann | Houston, Texas, USA

This activity is sponsored by Bristol Myers Squibb

PLENARY SESSION II

Session Chair: Hagop Kantarjian  

How I Treat PV Before and After Fibrotic Transformation | Ayalew Tefferi, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA

SESSION VI: CHRONIC MYELOID LEUKEMIA

State of the Art in CML: Update  |  Andreas Hochhaus, MD  |  University Medical Center Jena, Jena, Germany

SESSION VI: CHRONIC MYELOID LEUKEMIA

CML and Pregnancy  |  Elisabetta Abruzzese, MD, PhD  |  S.Eugenio University Hospital, Rome, Italy

SESSION VI: CHRONIC MYELOID LEUKEMIA

Oral Abstract - CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)  |  Jorge Cortés, MD |  Georgia Cancer Center at Augusta University, Augusta, Georgia, USA

SESSION VI: CHRONIC MYELOID LEUKEMIA

Update on TFR  |  Ehab L. Atallah, MD  |  Medical College of Wisconsin, Milwaukee, Wisconsin, USA

SESSION VI: CHRONIC MYELOID LEUKEMIA

Managing TKI Resistance: New Options  |  Delphine Rea, MD, PhD  |  Hôpital Saint Louis, Paris, France

SESSION VI: CHRONIC MYELOID LEUKEMIA

Case Study: Managing Cytopenias on TKI Therapy  |  Jane F. Apperley, MBChB, MD, FRCP, FRCPath  |  Hammersmith Hospital London Imperial College, London, United Kingdom

SESSION VII: MULTIPLE MYELOMA

Frontline Therapy for Amylodosis: Response Assessments  |  Angela Dispenzieri, MD  |  Mayo Clinic Rochester, Rochester, Minnesota, USA

SESSION VII: MULTIPLE MYELOMA

Salvage Therapy for Amyloidosis: Agents and Anti-Fibril Therapy  |  Suzanne Lentzsch, MD, PhD  |  Columbia University and at New York Presbyterian Hospital, New York, USA

SESSION VII: MULTIPLE MYELOMA

Frontline Therapy in TE NDMM: Pros and Con's; Quads, Early Transplant, Just Revlimid for Maintenance?   |  Amrita Y. Krishnan, MD, FACP  |  City of Hope National Medical Center, Duarte, California, USA

SESSION VII: MULTIPLE MYELOMA

Sequencing Treatment for Early Relapse: Which Triplets and When?  |  Maria-Victoria Mateos, MD, PhD  |  University Hospital of Salamanca, Spain

SESSION VII: MULTIPLE MYELOMA

Treatment of Triple Class Refractory Myeloma: Novel Agents  |  Robert Z. Orlowski, MD, PhD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

SESSION VII: MULTIPLE MYELOMA

Novel BCMA Targeted ADCs, Bispecific and Trispecific Antibodies  |  Saad Z. Usmani, MD, FACP  |  Levine Cancer Institute, Charlotte, North Carolina, USA

SESSION VII: MULTIPLE MYELOMA

BCMA Directed CAR T-Cells: Early Results and Future Directions  |  Jesus G. Berdeja, MD  |  Sarah Cannon Cancer Institute, Nashville, Tennessee, USA

SESSION VII: MULTIPLE MYELOMA

Oral Abstract - MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) |  Saad Z. Usmani, MD, FACP  | Levine Cancer Institute, Charlotte, North Carolina, USA 

INDUSTRY EXPERT SESSION VI

Considerations for Tailoring Treatment for First-Line and Relapsed/Refractory Follicular Lymphoma | Charles Farber, MD, PhD | Atlantic Medical Group, Morristown, New Jersey, USA

This activity is sponsored by Genentech

Industry Expert Session V

A Case-based Presentation on Improving Outcomes in Patients With Newly-Diagnosed Secondary AML

James McCloskey, MD | Chief of Leukemia | John Theurer Cancer Center | Hackensack University Medical Center, Hackensack, NJ
 

This activity is sponsored by Jazz Pharmaceuticals

INDEPENDENT SATELLITE SYMPOSIUM V

Personalizing Care for Patients with Low- to High-Risk MDS: Applying the Science to Real-World Case Scenarios

Chair: Guillermo Garcia-Manero, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Kelly S. Chien, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Rami S. Komrokji, MD | H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by an educational grant from Bristol Myers Squibb.
For more information and to register for this ISS, go to https://www.gotoper.com/go/soho2021mds-wc.

INDEPENDENT SATELLITE SYMPOSIUM VI

Medical Crossfire®: How Are We Meeting the Needs of Patients With CLL Across Lines of Care?

Chair: William G. Wierda, MD, PhD , The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Faculty: Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Faculty: Nitin Jain, MD, , The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
 

This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Genentech, Lilly and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
For more information and to register for this ISS, go to https://www.gotoper.com/go/soho2021cll-wc.

INDEPENDENT SATELLITE SYMPOSIUM VII

Regimen Choice and Newly Approved Agents in Relapsed/Refractory Multiple Myeloma

Chair: Sagar Lonial, MD, FACP | Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
Faculty: Tom Martin, MD | University of California San Francisco | San Francisco, California, USA
Krina Patel, MD, MSc | UT MD Anderson Cancer Center | Houston, Texas, USA

This CME activity is jointly provided by the University of Nebraska Medical Center and Bio Ascend. This activity is supported by  educational grants from Bristol Myers Squibb and Oncopeptides, Inc.

For more information and to register for this ISS, go to https://bioascend.com/featured-activities/sohomm2021/

INDEPENDENT SATELLITE SYMPOSIUM VII A

Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics

Co-Chair & Moderator, Srdan Verstovsek, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Co-Chair & Presenter, Ruben A. Mesa, MD, FACP | Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, Texas, USA

This educational live symposium is accredited by Medical Learning Institute, Inc. for CME/MOC.
This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education.
This activity is supported through educational grants from Bristol Myers Squibb, Constellation Pharmaceuticals, and Incyte Corporation.
For more information and to register for the live ISS, go to PeerView.com/MFHouston21-Live
To register for the webcast, go to PeerView.com/MF-Live2021

SESSION VIII: HODGKIN LYMPHOMA

Integrating Novel Agents into the Treatment of Classic Hodgkin Lymphoma  |  Ann Lacasce, MD, MMSc  |  Dana Farber Cancer Institute, Boston, Massachusetts, USA

SESSION VIII: HODGKIN LYMPHOMA

Treatment Strategies in Nodular Lymphocyte Predominant Hodgkin Lymphoma  |  Ranjana H. Advani, MD  |  Stanford University Medical Center, Stanford, California, USA

 SESSION IX: T-CELL LYMPHOMA

New Pathways and New Targets in PTCL  |  Ryan A. Wilcox, MD, PhD  |  University of Michigan, Ann Arbor, Michigan, USA

 SESSION IX: T-CELL LYMPHOMA

Moving Beyond BV-CHP in PTCL   |  Neha Mehta-Shah, MD  |  Washington University School of Medicine, St. Louis, Missouri, USA

 SESSION IX: T-CELL LYMPHOMA

Treatment of Advanced CTCL in 2021   |  Lauren C. Pinter-Brown, MD  |  UCI Health, Chao Family Comprehensive Cancer Center, Orange, California, USA

 SESSION IX: T-CELL LYMPHOMA

Immunotherapy Approaches in T-Cell Lymphoma   |  Maksim Mamonkin, PhD  |  Baylor College of Medicine, Houston, Texas, USA

 SESSION IX: T-CELL LYMPHOMA

Disparities in Treatment in Patients with T-Cell Lymphoma   |  Mary Jo Lechowicz, MD  |  Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

 SESSION IX: T-CELL LYMPHOMA

Oral Abstract - TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma | Swaminathan P. Iyer, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 

 SESSION X: INDOLENT B-CELL LYMPHOMA 

Molecular Pathogenesis of Follicular Lymphoma and Its Relevance to Clinical Practice  |  Jessica Okosun, MA, MB BChir, MRCP, FRCPath, PhD  |  Barts Cancer Institute, London, United Kingdom

 SESSION X: INDOLENT B-CELL LYMPHOMA 

Sequencing Therapy in Follicular Lymphoma  |  Peter Martin, MD  |  Weill Medical College of Cornell University, New York, New York, USA

 SESSION X: INDOLENT B-CELL LYMPHOMA 

Novel Therapies in Indolent Lymphoma  |  Loretta Nastoupil, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

 SESSION X: INDOLENT B-CELL LYMPHOMA 

Car T-Cell Therapy in Indolent Lymphoma  |  Caron A. Jacobson, MD, MMSc  |  Dana-Farber Cancer Institute, Boston, Massachusetts, USA

 SESSION X: INDOLENT B-CELL LYMPHOMA 

Oral Abstract - IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia | Jithma Abeykoon, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA 

INDUSTRY EXPERT SESSION VII

Treatment for CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma) and Waldenstroms Macroglobulinemia (WM | Moshe Y. Levy | Baylor University Medical Center

This activity is sponsored by Janssen Biotech & Pharmacyclics, LLC

Industry Expert Session VIII

A Treatment Option for Patients with Myelodysplastic Syndromes

Thomas William LeBlanc, MD | Duke University School of Medicine | Durham, North Carolina, USA
 

This activity is sponsored by Bristol Myers Squibb

PLENARY SESSION III

Session Chair: Moshe Talpaz

From Biology to Therapy: Progress in Hodgkin Lymphoma | Stephen M. Ansell, MD, PhD | Mayo Clinic Rochester, Rochester, Minnesota, USA

SESSION XI: AGGRESSIVE B-CELL LYMPHOMA

Dissecting the Biology of DLBCL: How Close Are We to a Clinically Validated Molecular Platform?  |  Georg Lenz, MD  |  University Hospital Münster, Münster, Germany

SESSION XI: AGGRESSIVE B-CELL LYMPHOMA

Innovative Approaches in Untreated DLBCL   |  Jason R. Westin, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

SESSION XI: AGGRESSIVE B-CELL LYMPHOMA

Sequencing Therapies in Transplant-Ineligible DLBCL   |  Laurie H. Sehn, MD, MPH  |  BC Cancer, Vancouver, Canada

SESSION XI: AGGRESSIVE B-CELL LYMPHOMA

The Next Wave of Novel Agents in Aggressive B-Cell Lymphoma   |  Gilles Salles, MD, PhD  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA

SESSION XI: AGGRESSIVE B-CELL LYMPHOMA

Update on Primary Mediastinal B-Cell Lymphoma   |  Kieron M. Dunleavy, MD  |  Georgetown University, Washington DC, USA

SESSION XI: AGGRESSIVE B-CELL LYMPHOMA

High Grade B-Cell Lymphoma : Double/Triple Hit and NOS   |  Andrew Davies, MD  |  University of Southampton, Southampton, United Kingdom

SESSION XI: AGGRESSIVE B-CELL LYMPHOMA

Oral Abstract - ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Brad S. Kahl, MD | Washington University Medical School, St. Louis, Missouri, USA 

SESSION XI: AGGRESSIVE B-CELL LYMPHOMA

Oral Abstract- ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts) | Cyrus Khan, MD | Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, USA 

SESSION XII: MANTLE CELL LYMPHOMA

Dissecting the Biology of Mantle Cell Lymphoma: What is Clinically Relevant  |  Thomas Witzig, MD  |  Mayo Clinic Rochester, Rochester, Minnesota, USA

SESSION XII: MANTLE CELL LYMPHOMA

Tailoring Upfront Therapy in Mantle Cell Lymphoma  |  Brad S. Kahl, MD  |  Washington University Medical School, St. Louis, Missouri, USA

SESSION XII: MANTLE CELL LYMPHOMA

Novel Treatment Approaches in Relapsed/Refractory MCL  |  Kami J. Maddocks, MD  |  Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio, USA

SESSION XII: MANTLE CELL LYMPHOMA

CAR T-Cell Therapy in Mantle Cell Lymphoma   |  Michael Wang, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Industry Expert Session IX

Monjuvi (Tafasitamab-Cxix) For Use As Second-Line Therapy in Adult Patients with R/R DLBCL, in Combination with Lenalidomide | Ruemu Ejedafeta Birhiray, MD | Hematology-Oncology of Indiana

This activity is sponsored by Incyte and MorphoSys

Industry Expert Session X

POLIVY+BR: Advance the Possibilities in R/R DLBCL, NOS, After at Least 2 Prior Therapies

John R. Pawloski, MD, PHD | Program Director, Cellular Therapy | Tampa General Hospital, Tampa, Florida, USA

This activity is sponsored by Genentech

INDEPENDENT SATELLITE SYMPOSIUM VIII

Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA

Sagar Lonial, MD | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
Thomas G. Martin, MD | University of California San Francisco, San Francisco, California, USA
Suzanne Lentzsch, MD, PhD | Columbia University and at New York Presbyterian Hospital, New York, USA
 

This CME activity is provided by Clinical Care Options, LLC. This activity is supported by an educational grant from GlaxoSmithKline.
For more information and to register for this ISS, go to TBD.

INDEPENDENT SATELLITE SYMPOSIUM V

Medical Crossfire®: How Are We Integrating New Treatment Strategies into the Care of Our B-Cell Lymphoma Patients?

Philippe Armand, MD, PhD | Dana-Farber Cancer Institute | Boston, Massachusetts, USA
Loretta J. Nastoupil, MD | The University of Texas MD Anderson Cancer Center | Houston, Texas, USA
Chair: Jason Westin, MD, MS, FACP | The University of Texas MD Anderson Cancer Center Houston, Texas, USA

This CME activity is provided by Physicians’ Education Resource, LLC.
This activity is supported by educational grants from Genmab USA, Inc., Incyte Corporation, Janssen Biotech, Inc., Pharmacyclics, an AbbVie Company and TG Therapeutics, Inc.

INDEPENDENT SATELLITE SYMPOSIUM X

CAR T Cell Therapy in Lymphoma and Myeloma in Clinical Practice

Christopher Flowers, MD | UT MD Anderson Cancer Center | Houston, Texas, USA
Loretta Nastoupil, MD | UT MD Anderson Cancer Center | Houston, Texas, USA
Noopur Raje, MD | Dana-Farber Cancer Institute | Boston, Massachusetts, USA

This activity is supported by independent educational grants from Bristol-Myers Squibb and Legend Biotech USA Inc. For more information and to register for this ISS, go to https://bioascend.rievent.com/a/RCOMAF.”

BREAKFAST WITH THE EXPERT II

Cell Therapy for Myeloma: When, Where, and What Type | Sergio Giralt, MD | Memorial Sloan-Kettering Cancer Center, New York, New York, USA

SESSION XIII: CELLULAR THERAPY 

Welcome and Opening Remarks  |  Melody Smith, MD, MS  |  Memorial Sloan-Kettering Cancer Center, New York, New York, USA

SESSION XIII: CELLULAR THERAPY 

Cytotoxic T Lymphocyte Therapy for Viral Infection  |  Amanda L. Olson, MD  |  The University of Texas at MD Anderson Cancer Center, Houston, Texas, USA

SESSION XIII: CELLULAR THERAPY 

NYESO Targeted TCRs  |  Adam J. Schoenfeld, MD  |  Memorial Sloan-Kettering Cancer Center, New York, New York, USA

SESSION XIII: CELLULAR THERAPY 

CAR T for Pediatric ALL: What's Next?  |  Stephan Grupp, MD, PhD  |  University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA

SESSION XIII: CELLULAR THERAPY 

Oral Abstract - CT-080: ATumor-Agnostic TCR-Mimic CAR-T cell Specific for NDC80 Targets Multiple Hematological Malignancies | Martin G. Klatt, MD | Memorial Sloan-Kettering Cancer Center, New York, New York, USA 

SESSION XIV: NEXT QUESTIONS

Session Chairs: Susan O'Brien and Hagop Kantarjian  

• Next Questions: Acute Lymphoblastic Leukemia  | Bijal Shah MD  |  H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

SESSION XIV: NEXT QUESTIONS

Next Questions: Acute Myeloid Leukemia  |  Hagop Kantarjian, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

SESSION XIV: NEXT QUESTIONS

Next Questions: Cellular Therapy  |  Marcela V. Maus,MD,PhD  |  Massachusetts General Hospital, Boston, Massachusetts, USA

SESSION XIV: NEXT QUESTIONS

Next Questions: Chronic Lymphocytic Leukemia  | Susan O'Brien, MD  |  UCI Health Chao Family Comprehensive Cancer Center, Orange, California, USA

SESSION XIV: NEXT QUESTIONS

Next Questions: Chronic Myeloid Leukemia  |  Jorge Cortés, MD  |  Georgia Cancer Center at Augusta University, Augusta, Georgia, USA

SESSION XIV: NEXT QUESTIONS

Next Questions: Aggressive B-Cell Lymphoma  |  Grzegorz S. Nowakowski, MD  |  Mayo Clinic Rochester, Rochester, Minnesota, USA

SESSION XIV: NEXT QUESTIONS

Next Questions: Indolent B-Cell Lymphoma  | Judith Trotman, MBChB, FRACP, FRCPA  |  Concord Repatriation General Hospital, Sydney, Australia

SESSION XIV: NEXT QUESTIONS

Next Questions: T-Cell Lymphoma  |  Barbara Pro, MD  |  Robert H Lurie Cancer Center, Northwestern University-Feinberg School of Medicine, Chicago, Illinois, USA

SESSION XIV: NEXT QUESTIONS

Next Questions: Mantle Cell Lymphoma  |  Martin Dreyling, MD, PhD  |  University of Munich, Munich, Germany

SESSION XIV: NEXT QUESTIONS

Next Questions: Hodgkin Lymphoma  | Craig H. Moskowitz, MD   |  University of Miami Health System, Miami, Florida, USA

SESSION XIV: NEXT QUESTIONS

Next Questions: Multiple Myeloma |  Ola C. Landgren, MD, PhD  |  University of Miami Health System, Miami, Florida, USA

SESSION XIV: NEXT QUESTIONS

Next Questions: Myelodysplastic Syndromes  |  Guillermo Garcia-Manero, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

SESSION XIV: NEXT QUESTIONS

Next Questions: Myeloproliferative Neoplasms  | Srdan Verstovsek, MD, PhD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

On-Demand Industry Expert Session I

BLENREP belantamab mafodotin-blmf for injection 100mg

Rafat Abonour, MD, Indianapolis, IN, USA

This activity is sponsored by GlaxoSmithKline

On-Demand Industry Expert Session II

BLENREP REMS: Real World Implementation and Best Practices

Cristina Gasparetto, MD, Associate Professor of Medicine, Durham, North Carolina, USA Mark Newman, OD, MS, Optix Eyecare Center, Durham, North Carolina, USA

This activity is sponsored by GlaxoSmithKline

On-Demand Industry Expert Session III

AYVAKIT: The ONLY Targeted Therapy for Advanced Systemic Mastocytosis Designed for Potent and Selective Inhibition of KIT D816V

Andrew Kuykendall, MD | H. Lee Moffitt Cancer Center, Tampa, Florida, USA

This activity is sponsored by Blueprint Medicines Corporation

On-Demand Industry Satellite Symposia I

Navigating Treatment Options for CML Across the Disease Continuum: An Expert Case- Based Discussion

Chair: Elias Jabbour | MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Faculty: Hagop M. Kantarjian, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Faculty: Shilpa Paul, PharmD, BCO | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by an educational grant from Novartis. For more information and to register for this ISS, go to https://www.gotoper.com/go/soho21cml

On-Demand Industry Satellite Symposia II

Advances in MF and PV: Individualizing Care Based on Patient- and Disease-Specific Factors

Chair: Srdan Verstovsek, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Faculty: Andrew Kuykendall, MD | Moffitt Cancer Center, Tampa, Florida, USA
Faculty: Raajit K. Rampal, MD, PhD | Memorial Sloan Kettering Cancer Center, New York, New York,
Faculty: Abdulraheem Yacoub, MD | The University of Kansas Medical Center, Kansas City, Kansas, USA

This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Bristol Myers Squibb, Incyte Corporation, Protagonist Therapeutics, SDP Oncology. For more information and to register for this ISS, go to https://www.gotoper.com/go/soho21mpn

On-Demand Industry Satellite Symposia III

Managing Multiple Myeloma from Newly Diagnosed to Relapsed/Refractory Settings: An Expert Case-Based Discussion

Chair: Saad Z. Usmani, MD, MBA, FACP | Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA
Faculty: Surbhi Sidana, MD | Stanford University, Stanford, California, USA
Faculty: Carlyn R. Tan, MD, Memorial Sloan Kettering Cancer Center, New York, New York, USA

This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Sanofi Genzyme, Karyopharm Therapeutics, Oncopeptides. For more information and to register for this ISS, go to https://www.gotoper.com/go/soho21mm

On-Demand Industry Satellite Symposia IV

How Can We Be More Strategic in Treatment Planning for Patients with ALL?

Chair: Elias Jabbour, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Faculty: Jae H. Park, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA
Faculty: Jerald P. Radich, MD | Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Amgen, Inc and Takeda Oncology.

On-Demand Industry Satellite Symposia V

Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Patients with Chronic Lymphocytic Leukemia

Faculty: Jeff Sharman, MD | Willamette Valley Cancer Institute and Research Center | Eugene, Oregon, USA
Faculty: Mitchell R Smith, MD, PhD | GW Cancer Center | Washington, DC, USA
Faculty: Philip A Thompson, MB, BS | The University of Texas MD Anderson Cancer Center | Houston, Texas, USA
Moderator: Neil Love, MD | Research To Practice | Miami, Florida, USA

This CME activity is provided by Research To Practice. This activity is supported by an educational grant from Bristol Myers Squibb

On-Demand Industry Satellite Symposia VI

Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Patients with Non-Hodgkin Lymphoma

Faculty: Andrew M Evens, DO, MSc | Rutgers Biomedical and Health Sciences, Rutgers University | New Brunswick, New Jersey, USA
Faculty: Ian W Flinn, MD, PhD | Sarah Cannon Research Institute | Nashville, Tennessee, USA
Faculty: Gilles Salles, MD, PhD | Memorial Sloan Kettering Cancer Center | New York, New York, USA
Moderator: Neil Love, MD | Research To Practice | Miami, Florida, USA

This CME activity is provided by Research To Practice. This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Incyte Corporation, Lilly, Novartis and TG Therapeutics Inc.